Carl Zeiss Meditec AG (ETR:AFX) has received an average rating of “Hold” from the nine research firms that are covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is €72.94 ($84.81).
AFX has been the subject of a number of analyst reports. Nord/LB set a €92.00 ($106.98) price target on Carl Zeiss Meditec and gave the company a “buy” rating in a research note on Monday, February 11th. HSBC set a €75.00 ($87.21) price objective on Carl Zeiss Meditec and gave the company a “buy” rating in a research report on Tuesday, December 4th. Hauck & Aufhaeuser set a €78.50 ($91.28) price objective on Carl Zeiss Meditec and gave the company a “buy” rating in a research report on Thursday, December 13th. Independent Research set a €73.00 ($84.88) price objective on Carl Zeiss Meditec and gave the company a “neutral” rating in a research report on Wednesday, December 12th. Finally, Deutsche Bank set a €71.00 ($82.56) price objective on Carl Zeiss Meditec and gave the company a “neutral” rating in a research report on Tuesday, December 11th.
Shares of ETR:AFX traded down €1.10 ($1.28) during mid-day trading on Wednesday, reaching €77.50 ($90.12). 103,389 shares of the stock were exchanged, compared to its average volume of 94,405. The company has a market cap of $7.03 billion and a PE ratio of 54.81. Carl Zeiss Meditec has a one year low of €48.60 ($56.51) and a one year high of €84.55 ($98.31).
Carl Zeiss Meditec Company Profile
Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, other Europe countries, and internationally. It operates through two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery.
Recommended Story: What are trading strategies for the 52-week high/low?
Receive News & Ratings for Carl Zeiss Meditec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Carl Zeiss Meditec and related companies with MarketBeat.com's FREE daily email newsletter.